Advertisement

Topics

Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R Pipeline Review, H2 2018 [Report Updated: 10072018] Prices from USD $3500

13:36 EDT 4 Aug 2018 | BioPortfolio Report Blog

Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R Pipeline Review, H2 2018


Summary


Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R pipeline Target constitutes close to 6 molecules. Out of which approximately 5 molecules are developed by companies and remaining by the universities/institutes. The latest report Interleukin 7 Receptor Subunit Alpha Pipeline Review, H2 2018, outlays comprehensive information on the Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type.


Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R Interleukin7 receptor is a protein found on the surface of cells. It is a receptor for interleukin7. It acts as a receptor for thymic stromal lymphopoietin TSLP. It plays an important role in Tcell acute lymphoblastic leukemia, multiple sclerosis, rheumatoid arthritis and juvenile idiopathic arthritis. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 2, 1 and 2 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively.


Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Central Nervous System, Gastrointestinal, Hematological Disorders and Women's Health which include indications Rheumatoid Arthritis, Type 1 Diabetes Juvenile Diabetes, Acute Lymphocytic Leukemia ALL, Acute Lymphoblastic Leukemia, Cervical Intraepithelial Neoplasia CIN, Crohn's Disease Regional Enteritis, Glioblastoma Multiforme GBM, Human Papillomavirus Infections, Idiopathic CD4 Lymphocytopenia, Melanoma, Merkel Cell Carcinoma, Metastatic Transitional Urothelial Tract Cancer, Multiple Sclerosis, NonSmall Cell Lung Cancer, Sepsis, Sicca Syndrome Sjogren, Solid Tumor, Squamous Cell Carcinoma, Transplant Rejection and Ulcerative Colitis.


Furthermore, this report also reviews key players involved in Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources.


Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope


The report provides a snapshot of the global therapeutic landscape for Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R

The report reviews Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industryspecific sources

The report covers pipeline products based on various stages of development ranging from preregistration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, RD brief, licensing and collaboration details other developmental activities

The report reviews key players involved in Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R targeted therapeutics and enlists all their major and minor projects

The report assesses Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R targeted therapeutics based on mechanism of action MoA, route of administration RoA and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R targeted therapeutics


Reasons to buy


Gain strategically significant competitor information, analysis, and insights to formulate effective RD strategies

Identify emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R development landscape

Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Original Article: Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R Pipeline Review, H2 2018 [Report Updated: 10072018] Prices from USD $3500

NEXT ARTICLE

More From BioPortfolio on "Interleukin 7 Receptor Subunit Alpha CDw127 or CD127 or IL7R Pipeline Review, H2 2018 [Report Updated: 10072018] Prices from USD $3500"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Nutrition
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...